List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Angina (Angina Pectoris) - Overview
Angina (Angina Pectoris) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Angina (Angina Pectoris) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Angina (Angina Pectoris) - Companies Involved in Therapeutics Development
Angionetics Inc
Ark Therapeutics Ltd
AstraZeneca Plc
Caladrius Biosciences Inc
Curacle Co Ltd
Eight Plus One Pharmaceutical Co Ltd
G. Pohl-Boskamp GmbH & Co KG
Hemostemix Inc
Imbria Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Kuhnil Pharmaceutical Co Ltd
Merck & Co Inc
Milestone Pharmaceuticals Inc
Signal Pharma Ltd
TSH Biopharm Corporation Ltd
VasThera Co Ltd
XyloCor Therapeutics Inc
Angina (Angina Pectoris) - Drug Profiles
ACP-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alferminogene tadenovec - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BJY-802 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-14 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CLBS-16 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CU-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EG-011 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
etripamil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IMB-1018972 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ivabradine hydrochloride SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KI-1007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
nitroglycerin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ranolazine ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Angina - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tirofiban hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTA-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
XC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
zibotentan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Angina (Angina Pectoris) - Dormant Projects
Angina (Angina Pectoris) - Discontinued Products
Angina (Angina Pectoris) - Product Development Milestones
Featured News & Press Releases
May 14, 2020: Caladrius Biosciences reports positive full results for CLBS16 from the ESCaPE-CMD trial at SCAI 2020 Scientific Sessions
May 06, 2020: Caladrius Biosciences announces presentation of full results for CLBS16 from the ESCaPE-CMD Trial at SCAI 2020 Scientific Sessions
Nov 16, 2019: Caladrius Biosciences reports positive results for CLBS16 from the ESCaPE-CMD trial at American Heart Association Scientific Sessions 2019
Oct 31, 2019: Caladrius Biosciences to participate at upcoming November conferences
Jun 04, 2019: Caladrius Biosciences completes enrollment in Phase 2 ESCaPE-CMD trial for Coronary Microvascular Dysfunction
Jul 18, 2018: Hemostemix announces first U.S. Patients treated in phase II clinical trial
Jun 19, 2018: Caladrius Receives FDA Regenerative Medicine Advanced Therapy Designation for CD34+ Cell Therapy for Treating Refractory Angina
Feb 07, 2017: FDA Grants Fast Track Designation To Angionetics' Generx Product Candidate, A One-Time Gene Therapy For Coronary Heart Disease
Sep 26, 2016: Espero Pharmaceuticals Announces the Availability of FDA-Approved GONITRO (Nitroglycerin) Sublingual Powder in the U.S.
Sep 12, 2016: Angionetics' Generx Gene Therapy Biologic Receives FDA Clearance For U.S. Phase 3 Clinical Study As A New, Single Dose, Treatment For Coronary Artery Disease
Aug 31, 2016: Espero Pharmaceuticals Selects DDB Health and Alamo Pharma Services as Partners for the Launch of GONITRO (Nitroglycerin) Sublingual Powder
Jun 14, 2016: Espero Pharmaceuticals Receives FDA Approval for GONITRO (Nitroglycerin) Sublingual Powder
May 11, 2015: Angionetics Presents At 2015 Annual Marcum MicroCap Conference On Business And Generx Clinical Development Activities
Jan 27, 2015: Taxus Cardium Announces Scientific Presentation And Clinical Update On Phase 3 Angiogenic Gene Therapy At The 2015 Phacilitate 11th Annual Cell & Gene Therapy Forum
Aug 13, 2014: Cardium Announces Review in Journal Of Cardiovascular Pharmacology Finds Gene Therapy For Subset Of Heart Disease Patients 'Highly Warranted'
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Angina (Angina Pectoris), H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Angina (Angina Pectoris) - Pipeline by Angionetics Inc, H2 2020
Angina (Angina Pectoris) - Pipeline by Ark Therapeutics Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by AstraZeneca Plc, H2 2020
Angina (Angina Pectoris) - Pipeline by Caladrius Biosciences Inc, H2 2020
Angina (Angina Pectoris) - Pipeline by Curacle Co Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by Eight Plus One Pharmaceutical Co Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by G. Pohl-Boskamp GmbH & Co KG, H2 2020
Angina (Angina Pectoris) - Pipeline by Hemostemix Inc, H2 2020
Angina (Angina Pectoris) - Pipeline by Imbria Pharmaceuticals Inc, H2 2020
Angina (Angina Pectoris) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by Kuhnil Pharmaceutical Co Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by Merck & Co Inc, H2 2020
Angina (Angina Pectoris) - Pipeline by Milestone Pharmaceuticals Inc, H2 2020
Angina (Angina Pectoris) - Pipeline by Signal Pharma Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by TSH Biopharm Corporation Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by VasThera Co Ltd, H2 2020
Angina (Angina Pectoris) - Pipeline by XyloCor Therapeutics Inc, H2 2020
Angina (Angina Pectoris) - Dormant Projects, H2 2020
Angina (Angina Pectoris) - Dormant Projects, H2 2020 (Contd..1), H2 2020
Angina (Angina Pectoris) - Discontinued Products, H2 2020

List of Figures
Number of Products under Development for Angina (Angina Pectoris), H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

Companies Mentioned
• Angionetics Inc
• Ark Therapeutics Ltd
• AstraZeneca Plc
• Caladrius Biosciences Inc
• Curacle Co Ltd
• Eight Plus One Pharmaceutical Co Ltd
• G. Pohl-Boskamp GmbH & Co KG
• Hemostemix Inc
• Imbria Pharmaceuticals Inc
• Jiangsu Hengrui Medicine Co Ltd
• Kuhnil Pharmaceutical Co Ltd
• Merck & Co Inc
• Milestone Pharmaceuticals Inc
• Signal Pharma Ltd
• TSH Biopharm Corporation Ltd
• VasThera Co Ltd
• XyloCor Therapeutics Inc